Modification of basal and GRF-stimulated cyclic AMP levels and growth hormone release by phospholipid metabolic enzyme inhibitors

Michael J. Cronin, Robert M. MacLeod, Pier L. Canonico

Risultato della ricerca: Contributo su rivistaArticolo in rivistapeer review

Abstract

The relative importance of several phospholipid pathways in cyclic AMP (cAMP) metabolism and growth hormone (GH) release was determined by an indirect, pharmacological approach in cultured anterior pituitary cells. The diglyceride lipase inhibitor RHC-80267 (30-100 μM) had no significant effect on cAMP levels but markedly inhibited basal and growth hormone-releasing factor- (GRF) stimulated GH secretion. A phospholipase A2 inhibitor quinacrine (30 μM) increased cellular cAMP content while decreasing GH release. Indomethacin, which reduces cyclooxygenase activity, affected neither cAMP levels nor GRF-enhanced GH release: This drug (30-100 μM) did reduce basal GH release. The lipoxygenase inhibitors nordihydroguaiaretic acid and BW-755c both reduced basal and GRF-stimulated GH release in a concentration-dependent manner. Both agents had various effects on cAMP levels. These results suggest that phospholipid metabolism, through both the cyclooxygenase and lipoxygenase pathways, contributes to basal GH release, wihle the lipoxygenase route predominates in GRF-stimulated GH release in vitro. Interestingly, cAMP metabolism can be dissociated from GH release with some of these probes, indicating an action of phospholipid metabolites distal or lateral to the cAMP-generating system.

Lingua originaleInglese
pagine (da-a)332-338
Numero di pagine7
RivistaNeuroendocrinology
Volume40
Numero di pubblicazione4
DOI
Stato di pubblicazionePubblicato - 1985
Pubblicato esternamente

Fingerprint

Entra nei temi di ricerca di 'Modification of basal and GRF-stimulated cyclic AMP levels and growth hormone release by phospholipid metabolic enzyme inhibitors'. Insieme formano una fingerprint unica.

Cita questo